Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDA approves Belviq to treat some overweight or obese adults.

Literature DB >> 23097775

FDA approves Belviq to treat some overweight or obese adults.

Abstract

Entities: Disease

Mesh：

Substances：
Benzazepines
lorcaserin

Year: 2012 PMID： 23097775

Source DB: PubMed Journal: Home Healthc Nurse ISSN： 0884-741X

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. A systematic investigation of the differential roles for ventral tegmentum serotonin 1- and 2-type receptors on food intake in the rat.

Authors: Wayne E Pratt; Kara A Clissold; Peagan Lin; Amanda E Cain; Alexa F Ciesinski; Thomas R Hopkins; Adeolu O Ilesanmi; Erin A Kelly; Zachary Pierce-Messick; Daniel S Powell; Ian A Rosner
Journal: Brain Res Date: 2016-07-16 Impact factor: 3.252

2. The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Authors: Anita Chawla; Ginger Carls; Edmund Deng; Edward Tuttle
Journal: Pharmacoeconomics Date: 2015-07 Impact factor: 4.981

Review 3. Obesity: Current and potential pharmacotherapeutics and targets.

Authors: Vidya Narayanaswami; Linda P Dwoskin
Journal: Pharmacol Ther Date: 2016-10-20 Impact factor: 12.310

Review 4. Weighing the Evidence of Common Beliefs in Obesity Research.

Authors: Krista Casazza; Andrew Brown; Arne Astrup; Fredrik Bertz; Charles Baum; Michelle Bohan Brown; John Dawson; Nefertiti Durant; Gareth Dutton; David A Fields; Kevin R Fontaine; Steven Heymsfield; David Levitsky; Tapan Mehta; Nir Menachemi; P K Newby; Russell Pate; Hollie Raynor; Barbara J Rolls; Bisakha Sen; Daniel L Smith; Diana Thomas; Brian Wansink; David B Allison
Journal: Crit Rev Food Sci Nutr Date: 2015 Impact factor: 11.176

FDA approves Belviq to treat some overweight or obese adults.

1. A systematic investigation of the differential roles for ventral tegmentum serotonin 1- and 2-type receptors on food intake in the rat.

2. The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Review 3. Obesity: Current and potential pharmacotherapeutics and targets.

Review 4. Weighing the Evidence of Common Beliefs in Obesity Research.

5. FDA approval of obesity drugs: a difference in risk-benefit perceptions.

Review 6. Pharmacotherapy for childhood obesity: present and future prospects.

Review 7. New pharmacological treatments for the management of obesity.

Review 8. Central nervous system biomarkers for antiobesity drug development.

9. A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss.

Review 10. Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity.